<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04661007</url>
  </required_header>
  <id_info>
    <org_study_id>INCMOR 0208-102</org_study_id>
    <nct_id>NCT04661007</nct_id>
  </id_info>
  <brief_title>To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)</brief_title>
  <acronym>J-MIND</acronym>
  <official_title>A Phase 1b Study of Tafasitamab, Tafasitamab Plus Lenalidomide, Tafasitamab Plus Parsaclisib, and Tafasitamab Plus Lenalidomide in Combination With R-CHOP in Japanese Participants With Non-Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Biosciences Japan GK</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter study to evaluate safety and tolerability, determine the&#xD;
      RP2Ds of tafasitamab anlone in Japanese participants with NHL., or tafasitimab in combination&#xD;
      with lenalidomide in in Japanese participants with R/R DLBCL, or tafasitimab in combination&#xD;
      with parsaclisib in in Japanese participants with R/R DLBCL or tafasitimab in combination&#xD;
      with lenalidomide plus R-CHOP in Japanese participants with previously untreated DLBCL.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2020</start_date>
  <completion_date type="Anticipated">November 21, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 24, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1,2 and 3 : Treatment Emergent Adverse Events (TEAE'S)</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Adverse events reported for the first time or worsening of a pre-existing event after first dose of study treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1,2, and 3 : Cmax of tafasitamab</measure>
    <time_frame>Approximately 27 months</time_frame>
    <description>Maximum observed serum concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1, 2, and 3 : Cmin of tafasitamab</measure>
    <time_frame>Approximately 27 months</time_frame>
    <description>Minimum observed serum concentration over the dose interval.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">49</enrollment>
  <condition>Non Hodgkins Lymphoma</condition>
  <condition>Diffuse Large B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Part 1 : tafasitimab monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose-finding to evaluate the safety and tolerability and to determine the RP2Ds of single-agent tafasitamab in Japanese participants with NHL. Part 1 consists of 2 groups: Group 1 will evaluate weight-based doses of tafasitamab, and Group 2 will evaluate fixed doses of tafasitamab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 : tafasitamab combination therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tafasitamab will be combined with lenalidomide (Group 3) or parsaclisib (Group 4a) in R/R DLBCL participants or lenalidomide plus R-CHOP (Group 5) in previously untreated DLBCL participants. The dose of tafasitamab will be based on the weight-based RP2D that is deemed safe and tolerable in Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3 : Dose Expansion of tafasitamab +parsaclisib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tafasitamab in combination with parsaclisib will be further evaluated in Group 4b at RP2D determined in Part 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tafasitamab</intervention_name>
    <description>tafasitamab will be administered at protocol defined timepoints based on the groups participants are assigned.</description>
    <arm_group_label>Part 1 : tafasitimab monotherapy</arm_group_label>
    <arm_group_label>Part 2 : tafasitamab combination therapy</arm_group_label>
    <arm_group_label>Part 3 : Dose Expansion of tafasitamab +parsaclisib</arm_group_label>
    <other_name>INCMOR00208</other_name>
    <other_name>MOR00208</other_name>
    <other_name>Xmab5574</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lenalidomide</intervention_name>
    <description>lenalidomide will be administered orally at protocol defined timepoints based on the groups participants are assigned.</description>
    <arm_group_label>Part 2 : tafasitamab combination therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>parsaclisib</intervention_name>
    <description>parsaclisib will be administered at protocol defined timepoints based on the groups participants are assigned.</description>
    <arm_group_label>Part 2 : tafasitamab combination therapy</arm_group_label>
    <arm_group_label>Part 3 : Dose Expansion of tafasitamab +parsaclisib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R-CHOP</intervention_name>
    <description>R-CHOP is a combination regimen consisting of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone. R-CHOP will be administered at protocol defined timepoints based on the groups participants are assigned.</description>
    <arm_group_label>Part 2 : tafasitamab combination therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Groups 1 and 2 only: Biopsy-proven participants with relapsed or refractory NHL of&#xD;
             DLBCL, FL or MZL..&#xD;
&#xD;
          -  Groups 3, and 4 only: Biopsy-proven participants with relapsed or refractory DLBCL..&#xD;
&#xD;
          -  Groups 5 only: Biopsy-proven participants with relapsed or refractory DLBCL..&#xD;
&#xD;
          -  Participants must have at least 1 bi-dimensionally measurable lesion.&#xD;
&#xD;
          -  -ECOG performance status of 0 to 2.&#xD;
&#xD;
          -  Participants with protocol defined laboratory criteria at screening&#xD;
&#xD;
          -  Groups 1 and 2 only:&#xD;
&#xD;
        Received at least 1 previous systemic therapy line for the treatment of NHL. At least 1&#xD;
        previous therapy line must have included a CD20-targeted therapy (eg, RTX).&#xD;
&#xD;
        -Groups 3, 4a, and 4b only: Received at least 1, but no more than 3, previous systemic&#xD;
        therapy lines for the treatment of DLBCL. At least 1 previous therapy line must have&#xD;
        included a CD20-targeted therapy (eg, RTX).&#xD;
&#xD;
        - Group 5 only: Participant must have: a. Untreated DLBCL. b. Ann Arbor Stage III to IV. c.&#xD;
        IPI status of 3 to 5 or age-adjusted IPI 2-3 (in Group 5 only). d. Appropriate candidate&#xD;
        for R-CHOP. e. LVEF of â‰¥ 50%, assessed by echocardiography.&#xD;
&#xD;
        -Willingness to avoid pregnancy or fathering children.&#xD;
&#xD;
        -In the opinion of investigator, the participant must: a. Not have a history of&#xD;
        noncompliance in relation to medical regimens or be considered potentially unreliable&#xD;
        and/or uncooperative.&#xD;
&#xD;
        b. Be able to understand the reason for complying with the special conditions of the&#xD;
        pregnancy prevention risk management plan and give written acknowledgement of this.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -Any other histological type of lymphoma&#xD;
&#xD;
          -  History of prior non-hematologic malignancy&#xD;
&#xD;
          -  Congestive heart failure requiring use of ongoing maintenance therapy for&#xD;
             life-threatening ventricular arrhythmias.&#xD;
&#xD;
          -  Participants with known positive test result for hepatitis C, and hepatitis B.&#xD;
&#xD;
          -  Known seropositive for or history of active viral infection with HIV.&#xD;
&#xD;
          -  Known active bacterial, viral, fungal, mycobacterial, or other infection at screening.&#xD;
&#xD;
          -  Known CNS lymphoma involvement - present or past medical history.&#xD;
&#xD;
          -  History or evidence of clinically significant cardiovascular, CNS and/or other&#xD;
             systemic disease that would in the investigator's opinion preclude participation in&#xD;
             the study or compromise the participant's ability to give informed consent.&#xD;
&#xD;
          -  History or evidence of rare hereditary problems of galactose intolerance, Lapp lactase&#xD;
             deficiency or glucose-galactose malabsorption.&#xD;
&#xD;
          -  History or evidence of interstitial lung disease.&#xD;
&#xD;
          -  Vaccination with live vaccine within 21 days prior to study treatment (Note:&#xD;
             throughout the study treatment period and at least 6 months after end of treatment,&#xD;
             vaccination with live vaccines should be avoided).&#xD;
&#xD;
          -  Major surgery within up to 30 days prior to signing the ICF, unless the participant is&#xD;
             recovered at the time of signing the ICF.&#xD;
&#xD;
          -  Any anticancer and/or investigational therapy within 14 days prior to the start of&#xD;
             Cycle 1&#xD;
&#xD;
          -  Gastrointestinal abnormalities including the inability to take oral study treatment,&#xD;
             requiring IV alimentation, or prior surgical procedure affecting absorption.&#xD;
&#xD;
          -  Pregnancy or lactation.&#xD;
&#xD;
          -  Groups 3 and 5 only: Participants who have history of deep venous thrombosis/embolism,&#xD;
             threatening thromboembolism, stroke or known thrombophilia or are at a high risk for a&#xD;
             thromboembolic event in the opinion of the investigator and who are not willing/able&#xD;
             to take venous thromboembolic event prophylaxis during the entire treatment period if&#xD;
             required&#xD;
&#xD;
          -  Groups 4a and 4b only: Use or expected use during the study of any restricted&#xD;
             medications, including potent CYP3A4 inhibitors or inducers within 14 days or 5&#xD;
             half-lives (whichever is longer) before the date of study treatment administration&#xD;
&#xD;
          -  Groups 1, 2, 3, 4a, and 4b only: Participants who have: a. Not discontinued&#xD;
             CD20-targeted therapy, chemotherapy, radiotherapy, investigational anticancer therapy,&#xD;
             or other lymphoma-specific therapy within the 14 days prior to Day 1 dosing.&#xD;
&#xD;
             b. In the opinion of the investigator, not recovered sufficiently from the adverse&#xD;
             toxic effects of prior therapies.&#xD;
&#xD;
             c. Previous treatment with CD19-targeted therapy (eg, CD19-CAR-T therapies, other CD19&#xD;
             mAbs including bispecific and ADCs).&#xD;
&#xD;
             d. Group 3 only: Been previously treated with IMiDs (eg, thalidomide or LEN). e. Group&#xD;
             4a and 4b only: Been previously treated with selective PI3KÎ´ or pan-PI3K inhibitors&#xD;
             (eg, idelalisib, copanlisib, duvelisib) and/or Bruton's tyrosine kinase inhibitors&#xD;
             (eg, ibrutinib).&#xD;
&#xD;
             f. A history of hypersensitivity to compounds of similar biological or chemical&#xD;
             composition to tafasitamab, IMiDs, and/or the excipients contained in the study&#xD;
             treatment formulations (citric acid monohydrate, polysorbate 20, sodium citrate&#xD;
             dehydrate and trehalose dihydrate).&#xD;
&#xD;
             g. Undergone ASCT within the period â‰¤ 3 months before the signing of the ICF.&#xD;
             Participants who have a more distant history of ASCT must exhibit full hematological&#xD;
             recovery before enrolment into the study.&#xD;
&#xD;
             h. Undergone previous allogenic stem cell transplantation. i. Concurrent treatment&#xD;
             other anticancer or experimental treatments.&#xD;
&#xD;
          -  Group 5 only: Participants who have: a. A history of radiation therapy to â‰¥ 25% of the&#xD;
             bone marrow for other diseases or history of anthracycline therapy.&#xD;
&#xD;
             b. A history of hypersensitivity or contraindication to any component of R-CHOP, LEN,&#xD;
             or compounds of similar biological or chemical composition as tafasitamab and/or the&#xD;
             excipients contained in the study treatment formulations or R-CHOP.&#xD;
&#xD;
             c. Contraindication to any of the individual components of R-CHOP. d. Any anticancer&#xD;
             and/or investigational therapy within 30 days prior to the start of Cycle 1, except&#xD;
             for permitted prephase treatment defined below.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Incyte Biosciences Japan GK Development Operations Call Center</last_name>
    <phone>+81 3-3507-5795</phone>
    <email>japan_clinicaltrials@incyte.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Chiba</city>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kyushu Cancer Center</name>
      <address>
        <city>Fukuoka</city>
        <zip>811-1395</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Suita-shi</city>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 1, 2020</study_first_submitted>
  <study_first_submitted_qc>December 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2020</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>INCMOR00208</keyword>
  <keyword>tafasitamab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.</ipd_time_frame>
    <ipd_access_criteria>Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://www.incyte.com/our-company/compliance-and-transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

